Valion Bio, Inc.
VBIO
$1.10
-$0.01-0.90%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 15.87% | -38.57% | -79.04% | -49.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 15.87% | -38.57% | -79.04% | -49.58% |
| Cost of Revenue | -- | 254.88% | -70.91% | -88.02% | -- |
| Gross Profit | -- | -429.55% | 80.00% | -70.06% | -- |
| SG&A Expenses | 365.58% | 40.55% | 34.10% | -12.28% | -114.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 653.97% | 68.85% | 43.67% | -13.17% | -111.61% |
| Operating Income | -562.75% | -73.52% | -52.76% | -1.69% | 86.72% |
| Income Before Tax | -572.60% | -81.41% | -52.53% | -1.42% | 86.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -572.60% | -81.41% | -52.53% | -1.42% | 86.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -92.89% | -81.41% | -52.53% | -1.42% | 34.15% |
| EBIT | -562.75% | -73.52% | -52.76% | -1.69% | 86.72% |
| EBITDA | -561.74% | -73.64% | -52.81% | -1.69% | 86.71% |
| EPS Basic | 21.60% | 49.09% | 59.16% | 85.32% | 94.37% |
| Normalized Basic EPS | -120.74% | 52.23% | 59.18% | 85.32% | 110.30% |
| EPS Diluted | 21.60% | 49.09% | 59.16% | 85.32% | 94.37% |
| Normalized Diluted EPS | -120.74% | 52.23% | 59.18% | 85.32% | 110.30% |
| Average Basic Shares Outstanding | 302.05% | 262.66% | 273.59% | 591.08% | 231.49% |
| Average Diluted Shares Outstanding | 302.05% | 262.66% | 273.59% | 591.08% | 231.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |